Plandai Biotechnology Inc (OTCMKTS:PLPL) has announced that USN (Ultimate Sports Nutrition) is developing a new range of products using its flagship product Phytofare. As per the reports, these products are being prepared based on the requirements of customers from New Zealand and Australia.
According to an agreement between both the companies, all the green tea based products of USN that are manufactured or sold in South African and European markets, are entitled to use Plandai Biotechnology’s Phytofare. Now, they have decided to get in touch with other manufacturers in USN’s portfolio to seek their help in selling the product in New Zealand and Australian markets. It’s a way to check if their relationship can bring fruitful results to both the companies or not.
Management’s Call
The senior management of Plandai is delighted to take the relation with USN to the next level. According to Callum Baylis-Duffield, Vice President, Sales & Marketing, Plandai, it’s great to see USN putting efforts to expand the market of Phytofare. Plandai hopes that such an effort from its partner company will surely help it cater a larger market share in the coming months.
Meanwhile, a well-known botanical therapeutics company named Herborium Group, Inc. (OTCMKTS:HBRM) has decided to come up with a host of next generation websites. Reports claim that Herborium seeks to promote its flagship product AcnEase through these websites. AcnEase is used to treat rosacea and acne, and these websites will help the company spread the words around the world.
Metabolix, Inc. (NASDAQ:MBLX) announced financial results for 2Q2015 ending June 30, 2015. Mdtabolix is one of the well-known advanced biomaterials companies in the world. At the end of the quarter, the company had a total of $22.7 million unrestricted cash in hand.
It used $5.5 million cash in various operating activities during the quarter against previous year’s $4.9 million. Company’s net loss from continuing operations in the second quarter was $6.1 million in 2Q2015 against $6.8 million of 2Q2014.
